NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|April 29, 2026

Dr Stephens on Preferring Continuous BTKi for High-Risk Del(17p) CLL

Author(s)Deborah Stephens, DO

Explore why high‑risk CLL often favors continuous BTK inhibitors over time‑limited venetoclax, balancing efficacy with clinic-visit burden.

Episodes in this series

2 experts are featured in this series

EP. 1 SEQUOIA Trial: Long-Term Zanubrutinib Efficacy in CLL

2 experts are featured in this series

EP. 2 SEQUOIA Outcomes in Patients With High-Risk Del(17p) CLL

2 experts are featured in this series

EP. 3 SEQUOIA Trial: Long-Term Safety Profile of Zanubrutinib in CLL

2 experts are featured in this series

EP. 4 Continuous Vs Fixed Duration Treatment in CLL

2 experts are featured in this series

EP. 5 Dr Stephens on Preferring Continuous BTKi for High-Risk Del(17p) CLL

2 experts are featured in this series

EP. 6 6-Year SEQUOIA Data With Zanubrutinib in Frontline CLL

2 experts are featured in this series

EP. 7 Frontline Zanubrutinib Efficacy in High-Risk Del(17p) CLL

2 experts are featured in this series

EP. 8 Zanubrutinib Safety Profile in CLL in Long-Term SEQUOIA Follow-Up

2 experts are featured in this series

EP. 9 Choosing Between Continuous and Fixed Dosing Options in Frontline

2 experts are featured in this series

EP. 10 Comparing BTKi Monotherapies in Frontline

Deborah Stephens, DO, explains why she prefers continuous BTKi vs time-limited options for patients with high-risk del(17p) chronic lymphocytic leukemia. She highlights the phase 3 SEQUOIA trial as key support for her preference and describes why patients from a lifestyle perspective would choosier continuous BTKi over fixed approaches.

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

Summary and Key Takeaways for First-Line EGFR-Mutant NSCLC With Brain Metastases

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Evolving Treatment Landscape and Future Directions n First-Line EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Subcutaneous Amivantamab and Q4W Dosing for First-Line EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Safety Profiles and Proactive Therapy Management of First-Line Regimens in EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

CNS Surveillance and Long-Term Management in EGFR-Mutant NSCLC With Brain Metastases

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Jason Aboudi Mouabbi, MD

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Tarantino, MD, PhD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan, MD, FASCO

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, PhD; Sarah Sammons, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Yelda Nouri, MD; Sara Nunnery, MD, MSCI

Louisiana Oncology Society

Louisiana Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

25th Annual International Congress on the Future of Breast Cancer® East

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

25th Annual International Congress on the Future of Breast Cancer® West

In-Person Event

25th Annual International Congress on the Future of Breast Cancer® West

July 17-18, 2026

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

1 Session is Available!

Rhode Island Oncology Society

Rhode Island Oncology Society

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Empire State Hematology & Oncology Society (New York)

Empire State Hematology & Oncology Society (New York)

2 Sessions are Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer

Epcoritamab Plus R2 Sustains Efficacy Across Subgroups in R/R Follicular Lymphoma

ASCO 2026 Highlights: Breast & Lung Cancer Advances With Ajaz Khan, MD

KLN-1010 In Vivo CAR Achieves 100% MRD Negativity in R/R Myeloma